The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Hybrid scheme with carboplatin and etoposide intravenous (iv) and oral in patients with small cell lung cancer: Should we treat in a different way based on the age?
Andrea Ruiz-ValdepeƱas
No relevant relationships to disclose
Magda Palka
No relevant relationships to disclose
Patricia Ibeas
No relevant relationships to disclose
Bernard Gaston Doger de Speville
No relevant relationships to disclose
Elena Almagro
No relevant relationships to disclose
David Perez Callejo
No relevant relationships to disclose
Miriam Huelves
No relevant relationships to disclose
Ana Lopez-Gonzalez
No relevant relationships to disclose
Constanza Maximiano
No relevant relationships to disclose
Miriam Mendez
No relevant relationships to disclose
Gema Nuevo
No relevant relationships to disclose
Mariano Provencio-Pulla
No relevant relationships to disclose